Skip to content

A Non-Randomized Study of the NightHawk Peripheral Plaque Excision System During Plaque Excision of Peripheral Arterial Disease

A Non-Randomized Study of the NightHawk Peripheral Plaque Excision System During Plaque Excision of Peripheral Arterial Disease

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00516308
Acronym
NightHawk
Enrollment
100
Registered
2007-08-15
Start date
2007-08-31
Completion date
2007-12-31
Last updated
2008-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Vascular Diseases

Keywords

CLI, Critical Limb Ischemia, PAD, Paripheral Arterial Disease, Artherosclerosis, Leg pain, Cardiovascular, Atherectomy, NightHawk

Brief summary

To assess the proximity of the catheter to the vessel wall and to correlate excised tissue with images collected by the integrated Optical coherence Tomography (OCT) imaging system. The primary endpoints are correlation between OCT images and histological characterization of excised tissue.

Interventions

DEVICENightHawk

Sponsors

FoxHollow Technologies
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Patient requires treatment for peripheral arterial disease (PAD). 2. Patient is willing and able to provide Informed Consent. 3. Patient has at least one focal, de novo infrainguinal lesion in a native vessel. 4. The minimum reference vessel diameter is 2.0 - 4.5 mm, dependent on the NightHawk device used. 5. The lesion is ≥ 50% stenosed by quantitative vascular angiography. 6. The lesion is ≤ 7 cm in length. 7. The patient must be able to take at least one form of anti-platelet or anti-thrombotic therapy.

Exclusion criteria

1. Patient presents with degree of limb disease or a co-existing medical condition that makes revascularization inappropriate. 2. The patient has diffuse peripheral arterial disease and/or the disease is heavily calcified. 3. Patient presents with concomitant disease contraindicating an endovascular intervention. 4. Patient is pregnant. 5. The patient has a hypersensitivity to contrast materials that cannot be adequately pretreated.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026